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Abstract
Background: The Study of Micardis (telmisartan) in Overweight/Obese patients with Type 2
diabetes and Hypertension (SMOOTH) compared hydrochlorothiazide (HCTZ) plus telmisartan
or valsartan fixed-dose combination therapies on early morning blood pressure (BP), using
ambulatory BP monitoring (ABPM).
Methods: SMOOTH was a prospective, randomized, open-label, blinded-endpoint, multicentre
trial. After a 2- to 4-week, single-blind, placebo run-in period, patients received once-daily
telmisartan 80 mg or valsartan 160 mg for 4 weeks, with add-on HCTZ 12.5 mg for 6 weeks (T/
HCTZ or V/HCTZ, respectively). At baseline and week 10, ambulatory blood pressure (ABP) was
measured every 20 min and hourly means were calculated. The primary endpoint was change from
baseline in mean ambulatory systolic and diastolic blood pressure (SBP; DBP) during the last 6
hours of the 24-hour dosing interval.
Results: In total, 840 patients were randomized. At week 10, T/HCTZ provided significantly
greater reductions versus V/HCTZ in the last 6 hours mean ABP (differences in favour of T/HCTZ:
SBP 3.9 mm Hg, p < 0.0001; DBP 2.0 mm Hg, p = 0.0007). T/HCTZ also produced significantly
greater reductions than V/HCTZ in 24-hour mean ABP (differences in favour of T/HCTZ: SBP 3.0
mm Hg, p = 0.0002; DBP 1.6 mm Hg, p = 0.0006) and during the morning, daytime and night-time
periods (p < 0.003). Both treatments were well tolerated.
Conclusion: In high-risk, overweight/obese patients with hypertension and type 2 diabetes, T/
HCTZ provides significantly greater BP lowering versus V/HCTZ throughout the 24-hour dosing
interval, particularly during the hazardous early morning hours.
Background
Hypertension, obesity and type 2 diabetes are cardiovas-
cular risk factors that commonly occur together. Insuffi-
cient suppression of the renin-angiotensin-aldosterone
system (RAAS) has been implicated in the development of
obesity-related high arterial pressure, and is linked with
insulin resistance and type 2 diabetes [1,2]. RAAS block-
ade may, therefore, be particularly beneficial in the anti-
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hypertensive treatment of patients with type 2 diabetes,
features of metabolic syndrome and obesity, particularly
as this population is poorly controlled. In a cross-sec-
tional prevalence study of 45,125 subjects from Germany,
hypertension (blood pressure [BP] ≥ 140/90 mm Hg) was
twice as common in obese as in non-obese patients (60.6
vs. 34.3%, respectively) [3]. Furthermore, BP control in
diagnosed and treated obese hypertensive patients was
extremely low (overall response [OR] = 0.8).
Adequate BP control is also overlooked during the morn-
ing hours. During this time there is typically a surge in BP,
which is associated with a high incidence of cerebro- and
cardiovascular events [4]. Consequently, the early morn-
ing hours are an important therapeutic target for antihy-
pertensive treatment [5].
Telmisartan is a once-daily angiotensin II receptor blocker
(ARB) with the longest plasma half-life of any ARB, pro-
viding 24-hour coverage of BP control from a single daily
dose; the angiotensin type 1 (AT1) versus AT2 receptor
affinity ratio for telmisartan is 3000-fold; however, it is
higher for valsartan (about 20,000-fold) [6-8]. In two ran-
domized studies of 1,279 hypertensive patients, telmisar-
tan 80 mg significantly reduced the early morning systolic
BP (SBP) surge compared with ramipril 10 mg [9].
Another ARB, valsartan has been shown to improve obes-
ity-related disorders, reduce body mass index (BMI) and
lower BP [10]. Based on such findings, it is therefore rele-
vant to compare telmisartan with valsartan. A previous
pooled analysis of two studies in patients with uncompli-
cated hypertension showed that telmisartan 80 mg pro-
vided SBP reductions in the last 6 hours of the dosing
interval and in the 24-hour mean that were superior to the
equipotent valsartan 160 mg (by 2.7 and 2.0 mm Hg,
respectively) [11]. In addition, two recent studies have
shown that telmisartan 80 mg plus hydrochlorothiazide
(HCTZ) 25 mg was superior to valsartan 160 mg plus
HCTZ 25 mg [12,13]. However, there are few studies com-
paring telmisartan and valsartan when used in combina-
tion with low-dose HCTZ 12.5 mg, and few direct ARB
comparisons in obese hypertensive patients with type 2
diabetes.
In this Study of Micardis (telmisartan) in Overweight/
Obese patients with Type 2 diabetes and Hypertension
(SMOOTH), the effect on early morning BP of the fixed-
dose combinations, telmisartan 80 mg plus HCTZ 12.5
mg (T/HCTZ) and valsartan 160 mg plus HCTZ 12.5 mg
(V/HCTZ), were compared using ambulatory BP monitor-
ing (ABPM). This is one of the largest ABPM studies per-
formed in obese hypertensive patients.
Methods
Men and women aged ≥ 30 years with mild-to-moderate
hypertension, defined as mean seated cuff SBP 140–179
mm Hg and/or diastolic BP (DBP) 95–109 mm Hg were
randomized. Patients were also required to have 24-hour
mean ambulatory SBP ≥ 130 mm Hg and/or DBP ≥ 85
mm Hg, type 2 diabetes that had remained stable and con-
trolled for ≥ 3 months, defined as glycolated haemoglobin
(HbA1C) ≤ 10% and a BMI ≥ 27 kg/m2 in non-Asians and
≥ 24 kg/m2 in Asians (patients' upper arm circumference
was required to be ≤ 52 cm to maximize the accuracy of
BP readings).
Patients were excluded from randomization if they had
mean seated SBP ≥ 180 mm Hg or mean seated DBP ≥ 110
mm Hg during any visit of the placebo run-in period, or
fasting serum glucose > 17 mmol/l (300 mg/dl). Premen-
opausal women who were nursing, pregnant or not using
adequate contraception were excluded. In addition,
patients with a history of coronary disease, congestive
heart failure, or a recent acute cardiovascular event (previ-
ous 3 months) or stroke (previous 6 months) were
excluded, as were those with secondary hypertension.
Patients were not eligible for randomization if they had
hepatic or renal impairment. Night-shift workers were
also excluded.
The use of corticosteroids, cholestyramine and colestipol
resins was prohibited throughout the SMOOTH study. In
addition, medications known to affect BP were not
allowed. These included vasopressors, vasodilators, beta-
agonists and -antagonists, nitroglycerin spray or sublin-
gual tablets, theophylline, dipyridamole, monoamine
oxidase inhibitors, phenothiazine and tricyclic antide-
pressants, chronic use of oral, nasal or topical decongest-
ants and antihypertensive medication other than the
study drugs.
Study design
SMOOTH (clinical trial number: 502.399) used a pro-
spective, randomized, open-label, blinded-endpoint
(PROBE), multicentre design. A published meta-analysis
has shown that blinded 24-h systolic and diastolic ambu-
latory BP results from PROBE studies evaluating antihy-
pertensive therapy were statistically equivalent to double-
blind, placebo-controlled (DBPC) studies. [14]. These
findings show that the PROBE study design is an attractive
and validated alternative to the DBPC design, particularly
in hypertension trials using ABPM. The PROBE design
maintains the strict randomization procedure, incorpo-
rates clearly defined (and blinded) endpoints that help
eliminate bias, and allows objective comparison of thera-
pies by an independent body.Cardiovascular Diabetology 2007, 6:28 http://www.cardiab.com/content/6/1/28
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After a 2- to 4-week, single-blind, placebo run-in period in
SMOOTH, patients who met inclusion and exclusion cri-
teria were randomized on a 1:1 basis to 4 weeks' mono-
therapy with either telmisartan 80 mg or valsartan 160
mg, after which all subjects received add-on HCTZ 12.5
mg for the following 6 weeks. Randomization, stratified
by study centre, was by an interactive voice response sys-
tem and determined using ClinPro/LBL Version 5.2 (Clin-
ical Systems, Inc. software, USA). Patients were instructed
to take study medication once daily in the morning with
water (and consistently with or without food) at approxi-
mately the same time each day (0900 hours ± 1 hour).
The SMOOTH study was conducted at 118 centres in
Argentina, Australia, Canada, Mexico, New Zealand,
South Korea, Taiwan and the USA, following approval by
the relevant local Institutional Review Board or central
Independent Ethics Committee, and according to the
principles of Good Clinical Practices. SMOOTH is part of
the PROTECTION Programme, which is supported by
Boehringer Ingelheim.
Efficacy and safety evaluations
ABPM was conducted at baseline (end of placebo run-in)
and week 10 using a Spacelab Model 90207 monitor (OSI
Systems Company, Issaquah, WA, USA), which was
applied before the patient took the scheduled study med-
ication. ABP was automatically measured every 20 min
during the 24-hour monitoring period following dosing,
with hourly means calculated relative to both the dosing
time and clock time. At each scheduled visit, clinic BP was
recorded using a mercury sphygmomanometer, and was
defined as the mean of three seated measurements col-
lected 2 min apart, after the patient had been seated qui-
etly for 5 min.
The primary endpoint in the SMOOTH study was the
change from baseline in mean ambulatory SBP and DBP
during the last 6 hours of the 24-hour dosing interval. Sec-
ondary endpoints were changes from baseline in mean
24-hour, morning (0600 hours to noon), daytime (noon
to 2200 hours), and night-time (2200 hours to 0600
hours) ambulatory SBP and DBP; changes in trough
seated clinic BP; and response rates based on both 24-
hour mean ambulatory SBP (24-hour mean SBP < 130
mm Hg and/or reduction ≥ 10 mm Hg) and DBP (24-
hour mean DBP < 80 mm Hg and/or reduction ≥ 10 mm
Hg). The incidence and severity of adverse events were
monitored throughout the study.
Statistics
For the primary endpoint, assuming standard deviations
of 12 and 8 mm Hg for SBP and DBP, a sample size of 337
evaluable patients per treatment group would have had
approximately 90% power to detect a treatment difference
of 3 mm Hg (SBP) and 2 mm Hg (DBP) at the 5% (two-
sided) level of significance.
Statistical analysis was performed on the full analysis set,
which included all patients who received a dose of study
medication and who had successful ABPMs at baseline
and at week 10. Treatment effects were compared by anal-
ysis of covariance, with treatment regimen and centre as
main effects, and the last 6-hour mean ABP at baseline as
covariate.
Testing of multiple endpoints (changes in the last 6-hour
mean ambulatory SBP and DBP) utilized a pre-defined
hierarchical testing procedure in the following order: (1)
comparison of treatment groups based on SBP; and (2) if
significant, comparison based on DBP. Thus, all signifi-
cance testing utilized a two-sided 5% level of significance.
Results
A total of 840 patients who met inclusion and exclusion
criteria were randomized to either T/HCTZ (n = 428) or V/
HCTZ (n = 412). Baseline characteristics of randomized
patients were comparable for the two treatment groups
and are shown in Table 1. About 10% of randomized
patients in each treatment group did not complete the
trial, most frequently as a result of adverse events (T/
HCTZ, n = 10 [2.3%]; V/HCTZ, n = 17 [4.1%]) or with-
drawal of consent (T/HCTZ, n = 11 [2.6%]; V/HCTZ, n =
6 [1.5%]). The full analysis set used for the efficacy analy-
ses included 743 patients (T/HCTZ, n = 378; V/HCTZ, n =
365) who had successful ABPM measurements at both
their baseline and final visits.
Reduction of ambulatory blood pressure in the last 6 hours 
of the 24-hour dosing interval
After 10 weeks' treatment, T/HCTZ provided significantly
greater mean BP lowering compared with V/HCTZ in the
last 6 hours of the 24-hour dosing interval (Figs. 1 and 2).
Mean SBP/DBP changes were -18.4/-9.7 mm Hg in T/
HCTZ-treated patients and -14.5/-7.7 mm Hg in V/HCTZ-
treated patients. This equates to a significant adjusted
mean difference in favour of T/HCTZ of 3.9 mm Hg (95%
confidence interval [CI] -5.8, -2.1) in SBP (p < 0.0001)
and 2.0 mm Hg (95% CI -3.2, -0.8) in DBP (p = 0.0007).
Overall, the mean BP was 139.1/82.4 mm Hg (V/HCTZ)
and 135.6/81.2 mm Hg (T/HCTZ).
Mean BP reductions in the last 6 hours were not signifi-
cantly affected by age group (< 65 years vs. ≥ 65 years) or
race. Women had significantly greater BP reductions than
men; 20.6/11.3 versus 16.8/8.4 mm Hg in patients taking
T/HCTZ, and 16.1/9.4 versus 13.4/6.5 mm Hg in those
taking V/HCTZ. However, the difference between treat-
ments was consistent in both genders.Cardiovascular Diabetology 2007, 6:28 http://www.cardiab.com/content/6/1/28
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Secondary endpoints
The changes from baseline in hourly means for SBP and
DBP after 10 weeks of treatment with either T/HCTZ or V/
HCTZ are shown in Figure 1, and the additional reduc-
tions with T/HCTZ versus V/HCTZ during various periods
are depicted in Figure 2. T/HCTZ produced significantly
greater reductions in 24-hour mean BP than V/HCTZ dur-
ing the 24-hour dosing interval (SBP 3.0 mm Hg, p =
0.002; DBP 1.6 mm Hg, p = 0.0006). In addition, during
the morning, daytime and night-time periods, patients
receiving T/HCTZ had significantly greater reductions in
mean ambulatory SBP and DBP compared with those tak-
ing V/HCTZ (p < 0.003) (Fig. 2). Ambulatory SBP
response rates were high in patients taking T/HCTZ
(79.9%) versus V/HCTZ (75.6%). Ambulatory DBP
response rates were similarly high in patients taking T/
HCTZ (79.9%) versus V/HCTZ (77.3%). Clinic DBP and
SBP response rates were also high in patients taking T/
HCTZ (80.6% and 82.3%, respectively) versus V/HCTZ
(75.5% and 75.0%). Clinic BP control (< 130/80 mm Hg)
was higher in patients taking T/HCTZ than V/HCTZ
(26.4% vs. 24.0%, respectively). Clinic DBP control was
also higher in the T/HCTZ group than V/HCTZ group
(77.4% vs. 71.9%, respectively).
Reductions in trough seated clinic BP after 10 weeks' treat-
ment were significantly greater with T/HCTZ compared
with V/HCTZ (SBP 3.2 mm Hg, p = 0.0017; DBP 1.2 mm
Hg; p = 0.0446). The advantage of telmisartan was already
apparent after 4 weeks of treatment with monotherapy
(SBP 2.5 mm Hg: p = 0.0106; DBP 0.8 mm Hg: p =
0.1370). The mean BP achieved with monotherapy was
146.6/86.3 mm Hg (valsartan) and 143.3/85.5 mm Hg
(telmisartan). Clinic BP control (< 130/80 mm Hg) was
also higher following monotherapy with telmisartan
compared with valsartan (13.6 vs. 10.6%, respectively)
although these values were still low. Clinic DBP control
was, however, much higher following monotherapy
(64.5% [telmisartan] and 63.1% [valsartan]).
Safety
The overall incidence of adverse events was low with at
least one adverse event reported by 158 T/HCTZ-rand-
omized patients (36.9%) and 151 (36.7%) V/HCTZ-rand-
omized patients. With the exception of dizziness, which
was reported in 14(3.3%) T/HCTZ-randomized patients
and one (0.2%) V/HCTZ-randomized patient, there were
no differences in the incidence of specific adverse events
between treatment groups.
Events were generally mild or moderate in intensity. Seri-
ous adverse events were reported by three (0.7%) patients
in each treatment group during monotherapy, and four
(1.0%) patients (T/HCTZ) and five (1.3%) patients (V/
HCTZ) during combination therapy. Adverse events
reported as serious were cardiac disorders (acute coronary
syndrome, unstable angina, coronary artery disease and
myocardial ischaemia), gastro-oesophageal reflux disease,
Table 1: Patient demographics and baseline characteristics of randomized patients.
T/HCTZ (n = 428) V/HCTZ (n = 412)
Gender (n [%])
Men 230 (53.7) 239 (58.0)
Women 198 (46.3) 173 (42.0)
Age
Mean ± SD (years) 58.5 ± 9.7 59.2 ± 9.7
≥ 65 years (n [%]) 122 (28.5) 119 (28.9)
Race (n [%])
White 292 (68.2) 292 (70.9)
Black 61 (14.3) 59 (14.3)
Asian 75 (17.5) 61 (14.8)
BMI
Mean ± SD (kg/m2) 33.6 ± 5.7 33.4 ± 5.3
Hypertension duration
Mean ± SD (years) 9.2 ± 9.5 8.9 ± 9.2
24-hour ABP
Mean SBP ± SD (mm Hg) 148.0 ± 11.9 147.8 ± 12.4
Mean DBP ± SD (mm Hg) 83.1 ± 9.2 83.3 ± 10.2
Trough seated BP
Mean SBP ± SD (mm Hg) 156.8 ± 12.5 157.1 ± 12.3
Mean DBP ± SD (mm Hg) 92.1 ± 9.3 91.7 ± 9.8
HbA1c (%)
Mean ± SD 7.0 ± 1.1 7.2 ± 1.2
ABP: ambulatory blood pressure; DBP: diastolic blood pressure; T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ; valsartan 160 mg plus 
HCTZ 12.5 mg; SBP: systolic blood pressure.Cardiovascular Diabetology 2007, 6:28 http://www.cardiab.com/content/6/1/28
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general disorders (asthenia, chest pain, cellulites), injury
(ankle fracture and joint dislocation), drug toxicity,
increased blood creatine phosphokinase, inadequately
controlled diabetes mellitus, athralgia, back pain, nervous
system disorders (carotid artery stenosis, cerebral haemor-
rhage, cerebral thrombosis, headache and intracranial
aneurysm), bipolar I disorder and vascular disorders
(hypertensive crisis and hypotension).
Treatment-related adverse events were infrequent in the T/
HCTZ (27, 6.3%) and V/HCTZ (22, 5.3%) treatment
arms; the most common were oedema (0 vs. 4 [1.0%]),
dizziness (5 [1.2%] vs. 0), and headache (4 [0.9%] vs. 6
[1.5%] for T/HCTZ and V/HCTZ, respectively). Labora-
tory markers at baseline and following T/HCTZ or V/
HCTZ treatment are summarized in Table 2. The addition
of HCTZ did not result in any significant metabolic distur-
bances.
Discussion
In a large, multicentre, PROBE study of overweight/obese
patients with hypertension and type 2 diabetes, once-
daily T/HCTZ was significantly more effective at lowering
BP than V/HCTZ during the last 6 hours of the 24-hour
dosing interval. T/HCTZ also produced significantly
greater BP reductions than V/HCTZ over the entire 24
hours. Both ARBs were well tolerated.
Patients enrolled in the SMOOTH study were at very high
risk of cardiovascular events and stroke because of the
presence of additive cardiovascular risk factors. In patients
with hypertension, antihypertensive agents are recom-
Changes from baseline in hourly means for (A) SBP and (B) DBP after treatment with T/HCTZ or V/HCTZ at 10 weeks Figure 1
Changes from baseline in hourly means for (A) SBP and (B) DBP after treatment with T/HCTZ or V/HCTZ at 10 weeks. 
Squares: T/HCTZ; triangles: V/HCTZ.Cardiovascular Diabetology 2007, 6:28 http://www.cardiab.com/content/6/1/28
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mended with a BP target of 140/90 mm Hg in patients
without diabetes and 130/80 mm Hg in those with diabe-
tes [15,16]. However, there are no specific recommenda-
tions for patients with coexisting hypertension, obesity
and type 2 diabetes.
Increased activity of the RAAS is associated with obesity-
linked hypertension and also with the development of
type 2 diabetes. Antihypertensive agents that block the
RAAS may be beneficial in patients with type 2 diabetes
and features of metabolic syndrome [2]. However, there
are few studies focusing on angiotensin blockade in the
management of the obese hypertensive patient. ARBs and
angiotensin-converting enzyme inhibitors (ACEis) may
have favourable metabolic effects in addition to their anti-
hypertensive properties that could be beneficial in these
obese patients [2]. This has already been shown with val-
sartan and irbesartan, both in combination with HCTZ
[17,18]. In another study, the Candesartan Role on Obes-
ity and on Sympathetic System (CROSS), candesartan was
found to have comparable BP lowering to HCTZ, but the
ARB also had a significant benefit on insulin sensitivity
[19]. The current study is novel, in that it is one of the first
to directly compare ARBs in such a large obese-hyperten-
sive population, and to monitor antihypertensive effec-
tiveness using 24-hour ABPM.
Furthermore, our study further confirms the superiority of
telmisartan versus valsartan, when both are used in fixed-
dose combination with HCTZ. Although physicians are
likely to use an up-titration approach to patient manage-
ment, there is now evidence to suggest that a fixed-dose
combination is beneficial in obese hypertensive patients,
and may help to overcome the barrier of poor patient
compliance as a result of polypharmacy or lack of efficacy
[20]. In the current study, the mean BP achieved with
monotherapy was 146.6/86.3 mm Hg (valsartan) and
143.3/85.5 mm Hg (telmisartan), which was improved to
139.1/82.4 mm Hg (valsartan) and 135.6/81.2 mm Hg
(telmisartan) when the patients were switched to low-
dose combination with T/HCTZ. The percentage of
patients achieving target BP (< 130/80 mm Hg) doubled
when patients were switched to combination therapy,
from 13.6% (telmisartan) to 26.4% (T/HCTZ) and from
10.6% (valsartan) to 24.0% (V/HCTZ).
Acute cardiovascular events and stroke show a strong cir-
cadian pattern. The highest incidence of events occurs in
the early morning hours, during which there is typically a
surge in BP [9]. Unfortunately, this vulnerable time period
coincides with a decline in efficacy of most antihyperten-
sive agents because they are relatively short acting. Differ-
ential effects between antihypertensive agents on the
magnitude of reduction in the early morning hours have
been shown in this and previous studies. Telmisartan has
Table 2: Summary of metabolic markers at baseline and on the last day of combination therapy.
T/HCTZ V/HCTZ Difference* 
(T/HCTZ – V/HCTZ)
Endpoint, mean ± SD Baseline Last day Baseline Last day p value
Serum triglyceride (mg/dL) 201.7 ± 247 211.8 ± 172 196.3 ± 151 210.5 ± 177 0.91
LDL-C (mg/dL) 165.6 ± 35.4 169.8 ± 38.1 162.8 ± 33.9 165.3 ± 36.0 0.17
HDL-C (mg/dL) 37.1 ± 6.5 36.6 ± 6.3 37.6 ± 7.2 37.1 ± 7.0 0.64
Total cholesterol (mg/dL) 195.7 ± 23.3 198.5 ± 21.7 194.5 ± 19.8 196.3 ± 20.9 0.20
Potassium (mEq/L) 4.4 ± 0.4 4.5 ± 0.4 4.4 ± 0.4 4.4 ± 0.4 0.03
Glucose (mg/dL) 128.8 ± 44.1 138.8 ± 53.1 134.1 ± 49.2 140.4 ± 55.2 0.58
HbA1c (%) 6.5 ± 0.3 6.6 ± 0.3 6.6 ± 0.3 6.7 ± 0.4 0.93
Albumin:creatinine ratio 97.6 ± 330 65.1 ± 266 66.7 ± 239 45.1 ± 177 0.97
T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ: valsartan 160 mg plus HCTZ 12.5 mg; LDL-C: low-density lipoprotein cholesterol; HDL-
C: high-density lipoprotein cholesterol; HbA1c: glycolated haemoglobin.
*Analysis of change from baseline
Additional reductions with T/HCTZ compared with V/HCTZ  in mean ambulatory SBP and DBP during various periods of  the 24-hour dosing interval after treatment for 10 weeks Figure 2
Additional reductions with T/HCTZ compared with V/HCTZ 
in mean ambulatory SBP and DBP during various periods of 
the 24-hour dosing interval after treatment for 10 weeks. 
Black: SBP; white: DBP.Cardiovascular Diabetology 2007, 6:28 http://www.cardiab.com/content/6/1/28
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shown superiority in the early morning hours over several
other antihypertensives, such as ramipril [21-23], losartan
[24,25], and valsartan [9]. In two large studies, telmisar-
tan 80 mg changed the overall mean systolic early morn-
ing surge by -1.5 mm Hg compared with a change of + 0.3
mmHg by the ACEi ramipril (p = 0.0049) [6]. In the
ATHOS study, telmisartan/HCTZ reduced 24-hour SBP to
a greater extent than amlodipine/HCTZ [26]. ATHOS
showed that antihypertensive agents with a long half-life,
such as telmisartan, can maintain efficacy throughout the
24-hour dosing period, thereby providing greater reduc-
tions in early morning BP than short-acting agents [6,27].
The improved early morning hypertension control with T/
HCTZ in the SMOOTH study may, therefore, be explained
by the 24-hour plasma elimination half-life of telmisartan
[28]. In contrast, valsartan has a shorter half-life of about
16 hours [6].
BP is strongly correlated with vascular (and overall) mor-
tality without any evidence of a threshold down to at least
115/75 mm Hg. This was demonstrated in a meta-analysis
of data from 61 prospective observational studies of
patients with vascular disease [29]. In the present study, T/
HCTZ provided significant additional reductions versus
V/HCTZ of 3.9 mm Hg in SBP and 2.0 in DBP during the
last 6 hours of the 24-hour dosing interval. Reductions of
this magnitude may be clinically meaningful. For exam-
ple, in the above meta-analysis, it was calculated that a
reduction in SBP of 2 mm Hg was associated with a 7%
reduction in risk of mortality from ischaemic heart disease
and a 10% reduction in risk of mortality from stroke [29].
In another study, reduction of early morning BP in
patients with type 2 diabetes, hypertension, and nephrop-
athy was associated with a significant slowing of the pro-
gression of renal damage [30].
In conclusion, in overweight/obese patients with hyper-
tension and type 2 diabetes, once-daily T/HCTZ was sig-
nificantly more effective than V/HCTZ during the last 6
hours of the 24-hour dosing interval, the time when most
cardiovascular events occur [31]. These findings indicate
significant potential treatment benefit of T/HCTZ for this
at-risk patient population. With strong evidence available
directly correlating BP reductions to cardiovascular and
cerebrovascular risk reduction, the additional efficacy
afforded by T/HCTZ over V/HCTZ may confer a clinical
advantage.
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